Human papillomavirus type 16 variant analysis of E6, E7, and L1 genes and long control region in biopsy samples from cervical cancer patients in north India by Pande, Shailja et al.
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2008, p. 1060–1066 Vol. 46, No. 3
0095-1137/08/$08.000 doi:10.1128/JCM.02202-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Human Papillomavirus Type 16 Variant Analysis of E6, E7, and L1
Genes and Long Control Region in Biopsy Samples from Cervical
Cancer Patients in North India
Shailja Pande,1 Neeraj Jain,1 Bhupesh K. Prusty,1 Suresh Bhambhani,2 Sanjay Gupta,2
Rajyashri Sharma,3 Swaraj Batra,4 and Bhudev C. Das1*
Division of Molecular Oncology1 and Division of Cytopathology,2 Institute of Cytology and Preventive Oncology (ICMR), I-7,
Sector 39, Noida 201301, India; Department of Obstetrics and Gynecology, JNMCH, Aligarh, India3; and
Department of Obstetrics and Gynecology, LNJP, New Delhi, India4
Received 14 November 2007/Accepted 2 January 2008
High-risk human papillomaviruses (HPVs), particularly HPV types 16 and 18 (HPV-16 and HPV-18,
respectively), play a cardinal role in the etiology of cervical cancer. The most prevalent type, HPV-16, shows
intratypic sequence variants that are known to differ in oncogenic potential and geographic distribution. This
study was designed to analyze sequence variations in E6, E7, and L1 genes and the LCR (for long control
region) of HPV-16 in cervical cancer patients to identify the most prevalent and novel HPV-16 variants and to
correlate them with the severity of the disease. Cervical biopsies from 60 HPV-16-positive cancer cases were
analyzed by PCR and DNA sequencing. The most frequently observed variations were T350G (100%) in E6,
T789C (87.5%) in E7, A6695C (54.5%) in L1, and G7521A (91.1%) in the LCR. In addition, only one novel
variant (T527A) in E6 and four new variants each in L1 (A6667C, A6691G, C6906T, and A6924C) and in the
LCR (C13T, A7636C, C7678T, and G7799A) were identified. While E7 was found to be highly conserved, the
variant 350G of E6 was the most prevalent in all of the histopathological grades. The majority of LCR variants
were found at the YY1 transcription factor binding sites. Interestingly, a complete absence of the Asian lineage
and a high prevalence of European lineages in E6, E7, L1, and the LCR (85, 86.7, 67.7, and 63.3%, respectively)
indicate a possible epidemiological linkage between Europe and India with regard to the dissemination of
HPV-16 infections in India.
Cervical cancer is the major cancer in Indian women and a
leading cause of cancer deaths. Every year, more than 130,000
new cases and about 70,000 deaths are recorded. The persis-
tent infection by specific types of high-risk human papilloma-
viruses (HR-HPVs) is essential for the progression of cervical
lesions (6, 11, 31, 60), and women who are infected with HR-
HPVs are likely to develop cancer (3, 4, 27, 40). Various
studies have demonstrated that more than 70% of invasive
cervical cancers harbor HPV type 16 (HPV-16) and HPV-18
(17, 31), and the products of viral transforming E6 and E7
genes have been shown to contribute to tumorigenesis by func-
tionally inactivating two important cellular tumor suppressor
proteins, p53 and retinoblastoma (5, 14, 30, 55).
More than 100 types of HPV are known, but only about 30
types are associated with anogenital cancer. According to the
Papillomavirus Nomenclature Committee, a new HPV type is
defined by a nucleotide sequence variation of more than 10%
compared to that of other known HPV types in the E6, E7, and
L1 open reading frames. Those differing by 2 to 10% are
referred to as subtypes, whereas intratype variants may vary by
up to 2% in the coding region and 5% in the noncoding region
compared to that of the prototype (2, 10).
On the basis of sequence variations in E6, L1, L2, and the
long control region (LCR), HPV-16 variants have been iden-
tified and grouped into six distinct phylogenetic branches: E
(European), AA (Asian-American), Af1 (African 1), Af2 (Af-
rican 2), As (Asian), and NA (North American) (54, 56, 57).
These variants have been found to show different geographic
distributions, with various oncogenic potentials. A number of
sequence variations have been reported for HPV-16 E6, E7,
and L1 genes as well as in the LCR in cervical cancer (33, 39,
48, 55, 56). Studies also have shown that specific intratype
variants may influence the persistence of HPV infection and
the progression of precursor lesions to cancer (27, 58, 59).
HPV variants also may affect virus assembly, immunologic
responses, pathogenicity, p53 degradation, immortalization
activity, and the regulation of transcription (15, 18, 24, 25,
37, 51). These variations immediately affect the sensitivity
and specificity of different PCR-based genotype diagnostic
methods.
Of the two HPV-16 oncogenes E6 and E7, E6 has been
found to show more variations than E7, which is relatively
conserved (48, 50, 56, 58, 59). The analysis of the L1 gene,
which codes for the viral major capsid protein, is of immense
importance because of its high diagnostic value. The range of
intratype variation observed in this region allows the distinc-
tion and assessment of known and novel HPV types (46). This
is also an important target for the development of HPV vac-
cines. Very few reports are available on HPV variants from this
region (9, 56). The LCR, which regulates viral transcription,
has been found to be the most variable region of the HPV-16
genome (41, 53, 56). Several authors have evaluated the asso-
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ciation of specific HPV-16 variants with viral persistence and
the development of cervical intraepithelial neoplasia lesions (3,
27, 34, 50, 52).
In India, as high as 98% of the cervical carcinoma cases are
found to harbor HPV infection, and the most prevalent
(80%) type is HPV-16 (7, 8, 22). Although the prevalence of
HPV and cervical cancer in India is the highest in the world,
there is not much information on HPV variants from different
regions of the Indian subcontinent. In the present study, we
have examined the sequence variations in E6, E7, and L1 genes
and the LCR of the most prevalent HR-HPV type, HPV-16,
and correlated them with the age of the women, histopatho-
logic grades of tumors, and oncogenic potential.
MATERIALS AND METHODS
Study population and specimen collection. Out of a total of 90 tumor samples
screened by standard procedures (20, 38), 60 HPV-16-positive cervical cancer
cases were recruited for the variant analysis in the present study. The tumor
samples were from biopsies collected for the routine diagnosis of cervical cancer
from the Cancer Clinic of the Department of Gynecology and Obstetrics, Lok
Nayak Hospital, New Delhi, India, and Jawaharlal Nehru Medical College,
Aligarh, India. Fresh tumor biopsies were collected in chilled phosphate-buffered
saline (PBS) and stored at 70°C in a deep freezer for further processing later.
Informed consent was obtained from all patients, and the study was approved by
the institutional ethical committee. The diagnosis of histopathological grades was
done independently by two pathologists. Discrepancies were resolved by a third
pathologist to arrive at a final decision.
DNA extraction and typing of HPV. High-molecular-weight genomic DNA
from cervical biopsies was isolated by the standard method of proteinase K
digestion and phenol-chloroform extraction that is routinely followed in our
laboratory (8, 20).
The detection of HPV and the typing of HR-HPV-16 and HR-HPV-18 were
carried out using consensus and type-specific primers described earlier (20, 38).
The amplification of the -globin gene served as the internal control. PCR was
performed using the in-house PCR protocol that is routinely followed in our
laboratory (7, 8, 17). Briefly, the method involved a 25-l reaction mix containing
100 to 200 ng DNA, 10 mM Tris-Cl (pH 8.4), 50 mM KCl, 1.5 mM MgCl2, 12.5
M of each deoxynucleoside triphosphate (dATP, dCTP, dGTP, and dTTP), 5
pmol of each oligonucleotide primer, and 0.5 U Taq DNA polymerase (Applied
Biosystems). The temperature profile used for amplification was an initial dena-
turation at 95°C for 5 min, followed by 30 cycles with denaturation at 95°C for
30 s, annealing at 55°C for 30 s, and extension at 72°C for 30 s, which was
extended for 4 min in the final cycle. The oligonucleotide primers were synthe-
sized in an automated Applied Biosystems DNA synthesizer (model 381A; Fos-
ter City, CA) and purified by high-pressure liquid chromatography.
Variant analysis of E6, E7, and L1 genes and the LCR of HPV-16 by PCR and
direct sequencing. HPV-16 E6-, E7-, and LCR-specific PCRs were performed
with the following specific primers: for HPV-16 E6 (nucleotide [nt] 83 to 559)
with an amplicon size of 476 bp, 5-GAA ACC GGT TAG TAT AAA AGC
AGA C-3 and 5-AGC TGG GTT TCT CTA CGT GTT CT-3; for E7 (nt 562
to 858) with an amplicon size of 296 bp, 5-CCA TAA TAT AAG GGG TCG
GTG GA-3 and 5-TTT TTC CAC TAA CAG CCT CTA CAT-3; for the LCR
(nt 7437 to 7456 and nt 119 to 147) with an amplicon size of 617 bp, 5-CCA TTT
TGT AGC TTC AAC CCG-3 and 5-AAG TGT GGT AAC TTT CTG GGT
CGC TCC TG-3(54). The L1 gene was amplified partially (450 bp) using MY
11/MY 09, the consensus primer, with sequences 5-GCM CAG GGW CAT
AAY AAT GG-3 and 5-CGT CCM ARR GGA WAC TGA-3, where M  A
and C, W  A and T, Y  C and T, and R  A and G (38).
For variant analysis, the PCR products were directly sequenced on an auto-
mated DNA sequencer (310 ABI Prism genetic analyzer; Applied Biosystems)
according to the manufacturer’s protocol. PCR products first were purified using
an ammonium acetate-ethanol precipitation method to remove unused de-
oxynucleoside triphosphates and primers and then cycle sequenced using the
BigDye Terminator sequencing ready reaction mix (Applied Biosystems) on a
Gene Amp PCR 9700 (Applied Biosystems). The raw data were collected using
ABI Prism 310 collection software, analyzed using sequencing analysis software
(version 3.4.1) on a Macintosh operating system (version 9.1), and compared to
the sequence of GenBank/EMBL/DDBJ sequence no. U89348. All of the sam-
ples were reverse sequenced to corroborate the findings.
Identification of variants. Variants were identified using the prototype se-
quence (HPV-16R), which belongs to the European lineage, as the standard for
comparisons and nucleotide position numbering (32), and variants were classi-
fied into the six major branches European (E), Asian-American (AA), Asian
(As), African 1 (Af1), African 2 (Af2), and North American (NA), as described
by Yamada et al. (56).
Statistical analysis. The statistical analysis was performed using the 2 test to
determine the association between HPV-16 variants and the age and histopatho-
logic status of the cancer patients. Fisher’s exact test was employed for compar-
isons of small numbers. A P value of less than 0.05 was considered statistically
significant.
RESULTS
Out of 90 cervical tumor samples screened with L1 consen-
sus primers, 65 (72.2%) were positive for HPV, and further
genotyping with type-specific primers revealed 92.3% (n  60)
positivity for HPV-16 and 7.7% (n  5) positivity for HPV-18.
All 60 patients recruited were exclusively infected with HPV-
16, and none of them showed the presence of HPV-18. The
patients were 30 to 80 years old, with a mean age of 51.3 years
(standard deviation, 12.8). The patients were divided into two
age groups: 30 to 50 years and more than 50 years. All of the
cases were of squamous cell carcinoma (SCC); 23 (38.3%)
were well-differentiated (WDSCC), 35 (58.3%) were moder-
ately differentiated (MDSCC), and 2 (3.4%) were poorly dif-
ferentiated squamous cell carcinomas (PDSCC). The E6, E7,
and L1 genes and the LCR were analyzed for nucleotide vari-
ations and were compared to the prototype sequence HPV-
16R of the E lineage.
Association between HPV variants and histopathological
grades. For the E6 gene, variants were found to be more com-
mon than the prototype in both WDSCC (68.2%) and MDSCC
(65.8%) cases (the MDSCC cases include two PDSCC cases),
while the prototypes of E7 (86.4 and 86.8%, respectively) and L1
(60.0 and 66.7%, respectively) (Table 1) were more common than
variants. The frequency of LCR variants also was found to be
higher in WDSCC and MDSCC (81.8 and 71.1%, respectively)
than that of the prototype (Table 1).
E6 sequence variations. Nucleotide sequences of the com-
plete E6 open reading frame in all 60 cancer patients screened
were compared to the HPV-16 reference sequence. Forty-two
(70%) patients showed seven different types of E6 gene mu-
tations, of which four, G145T, C335T, T350G, and T527A,
were missense mutations: glutamine3histidine (Q14H), histi-
dine3tyrosine (H78Y), leucine3valine (L83V), and serine3
TABLE 1. Association of histopathological diagnosis with variants
of E6, E7, the LCR, and L1
Gene
No. (%) of cases exhibiting the prototype or variant
gene according to carcinoma type
PWDSCC (n  22) MDSCCb (n  38)
Prototype Variant Prototype Variant
E6 7 (31.8) 15 (68.2) 13 (34.2) 25 (65.8) 0.84
E7 19 (86.4) 3 (13.6) 33 (86.8) 5 (13.2) 0.95
LCR 4 (18.2) 18 (81.8) 11 (28.9) 27 (71.1) 0.35
L1a 6 (60.0) 4 (40.0) 14 (66.7) 7 (33.3) 0.71
a Variant analysis for L1 was done for only 31 cases (WDSCC, n  10;
MDSCC, n  19; and PDSCC, n  2).
b Two cases of PDSCC showing only prototype sequences were grouped with
MDSCC cases.
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threonine (S142T), respectively. The remaining three, T286A,
A289G, and A532G, led to silent mutations at codons 61, 62, and
143 for amino acids alanine, valine, and serine, respectively.
The most frequently observed mutation was the European
variant T350G (Fig. 1a), which was detected in all 42 (100%)
patients either alone (34 [81%]) or along with other variants (8
[19%]) (Fig. 2). Additional E6 gene variations were observed
only in those cases that showed the 350G variation, and no case
with the 350T sequence had any nucleotide change. The ma-
jority of cases (85%) were found to be of E lineage, 10%
belonged to branch NA, 3.3% to AA, and none to As, Af1, or
Af2 (see Table 3). Interestingly, a novel mutation, T527A, was
recorded along with 350G (Fig. 2) for the first time.
E7 sequence variations. The E7 gene revealed only five
nucleotide variations in 8 (13.3%) patients, whereas the other
52 (86.7%) cases showed the prototype sequence. All of the
variants were silent nucleotide alterations; one was a transver-
sion, and the other four were transition substitutions. The
silent mutations detected were G666A, T732C, T789C, T795G,
FIG. 1. Sequencing electropherogram showing frequently detected
nucleotide variations in different genomic segments of HPV-16. (a) E6
T350G; (b) E7 T789C; (c) L1 A6695C; and (d) LCR G7521A. The
upper panel shows prototype sequences, while the lower panel shows
variant sequences (indicated by arrows).
FIG. 2. Nucleotide sequence variations among the HPV-16 isolates. The nucleotide positions of E6, E7, the LCR, and L1 at which variations
were observed are written across the top. The identification codes of the samples are indicated on the left. REF, the HPV-16 reference DNA
sequence. For each variant sequence, positions that do not vary from those of the HPV reference sequence are marked with dashes.
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and T828C for the amino acids glutamic acid (E), phenylala-
nine (F), isoleucine (Il), threonine (T), and isoleucine (Il) at
codons 35, 57, 76, 78, and 89, respectively. E7 sequencing data
indicated that 86.7% belonged to branch E (prototype), 11.6%
to Af2, 1.7% to As, and none to NA, AA, or Af1 (see Table 3).
L1 sequence variations. A partial sequence of the L1 gene
was screened using a 450-bp amplicon for samples from 31
cervical cancer patients. A total of 13 nucleotide variations
were detected in 11 (35.5%) patients, while the majority (20
[64.5%]) showed the prototype sequence. Of 13 variants, 5
(38.5%) led to missense mutations and 8 (61.5%) led to silent
mutations.
Of four variants found independently (Fig. 2), two were silent
mutations, A6667C and A6691G, coding for serine at codons 343
and 351, whereas A6803T and A6964C led to the missense mu-
tations threonine3serine (T389S) and lysine3asparagine
(K442N). The most frequently detected L1 variation, A6695C
(Fig. 1c), was found in six (54.5%) cases. Interestingly, four novel
L1 variants consisting of two silent mutations, at A6667C and
A6691G, and two missense mutations, serine3phenylalanine
(S423F) at C6906T and glutamine3proline (Q429P) at A6924C,
were observed (Table 2). The novel L1 variants that exhibited
silent mutations had only prototype sequences at E6 and E7 gene
regions and the LCR (Fig. 2). The L1 sequence data showed that
67.7% belonged to branch E, 3.2% to branch E (G131), 12.9% to
AA, 6.5% to NA, and none to As, Af1, or Af2; 9.7% were new
variants (Table 3).
LCR sequence variations. The LCR of HPV-16 showed the
highest number of nucleotide variations in various known and
unknown regulatory binding sites of a number of cellular
and/or viral transcription/regulatory factors. A total of 45
(75%) variant cases that were analyzed showed 17 different
point mutations (nine transitions and eight transversions). Of
these, seven (G7521A, A7636C, C7689A, T7714G, C7792T,
G7826A, and A7839C) were detected in the known binding
sites for various transcription factors, such as YY1, AP1,
TEF1, NF1, and Oct-1. The most commonly observed LCR
variation was the transition substitution G7521A (Fig. 1d),
which was detected in 41 (91.1%) patients at one of the many
YY1 binding sites. This mutation occurred alone in as many as
22 (53.7%) cases (Fig. 2).
Another frequently observed LCR variation was a transver-
sion mutation, T7714G, detected in nine (20%) cases, mostly
along with G7521A, which is located in the NF1 transcription
factor binding site. Two other LCR variants, T7743G and
C7764T, were detected upstream of the NF1 binding site in
11.1 and 22.2% of cases, respectively. We report here four
novel LCR variants, C13T, A7636C, C7678T, and G7799A
(Table 2), of which three were transition mutations and one
(A7636C) was a transversion mutation located at the AP1
binding site.
A phylogenetic classification of LCR variants was found to
exhibit the same pattern as that observed for E6, E7, and L1,
showing that a majority (63.3%) belonged to branch E (P),
13.3% to AA, 11.6% to Af1, 3.3% to Af2, and none to NA or
As. Four (8.3%) novel LCR variants were observed for the first
time from India (Table 3).
DISCUSSION
HPV variant data are important in developing HPV diag-
nostics, vaccines, and other therapeutic approaches to control
virus-induced diseases. HPV-16 variants have been shown to
have different biological as well as biochemical effects, result-
ing in altered oncogenic potentials (1, 47, 59). The oncogenic-
ity of distinct HPV variants also may differ between geograph-
ical regions because of differences in the population related to
the distribution of HLA alleles (28).
Nucleotide sequence variations observed in E6, E7, and L1
genes and the LCR of HPV-16 in 60 cervical carcinoma cases
showed a high prevalence of 350G E6 variants (the prototype is
TABLE 2. Novel variants of HPV-16 E6, L1, and the LCR according to nucleotide position, variant, altered amino acid, and mutation
Gene Nucleotideposition
Nucleotide Amino acid
Codon no. Type ofmutationa
No. (%) of
mutationsPrototype Variant Original Altered
E6 527 T A Serine Threonine 142 M, Ts 1 (2.4)
L1 6667 A C Serine Serine 343 S, Tv 2 (18.2)
6691 A G Serine Serine 351 S, Ts 1 (9.1)
6906 C T Serine Phenylalanine 423 M, Ts 2 (18.2)
6924 A C Glutamine Proline 429 M, Tv 1 (9.1)
LCR 13 C T Ts 2 (4.4)
7636 A C Tv 2 (4.4)
7678 C T Ts 1 (2)
7799 G A Ts 2 (4.4)
a M, missense; S, silent; Ts, transition; Tv, transversion.
TABLE 3. Frequency distribution of HPV-16 variants in different
phylogenetic lineages
Lineage
No. (%) of variants for gene:
E6 (n  60) E7 (n  60) L1 (n  31) LCR (n  60)
E (P) 52 (86.7) 21 (67.7) 38 (63.3)
E - P (350T)a 18 (30)
E - P (350G)b 33 (55)
E (G131) 1 (3.2)
AA 2 (3.3) 4 (12.9) 8 (13.3)
NA 6 (10) 2 (6.5)
Af1 7 (11.6)
Af2 7 (11.6) 2 (3.3)
As 1 (1.7)
New variant(s) 1 (1.7) 3 (9.7) 5 (8.3)
a Prototype of E6.
b Typical HPV-16 variant of E6.
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350T) in all of the histopathologic grades (WDSCC, MDSCC,
and PDSCC). This is in good agreement with previous reports (1,
59), which demonstrated an increased frequency of 350G E6
variants in cervical cancer leading to an amino acid change of
leucine to valine at position 83 (L83V), and this has been asso-
ciated with the progression of cervical lesions (59). In contrast,
several authors failed to find a significant role of the E6 variants
in cervical cancer (19, 33, 50). A study of the prevalence of the E6
gene mutations in a subset of south Indian cervical cancer pa-
tients found only 20% of cancer patients with 350G variants,
which is in sharp contrast to the present study, which shows that
78% of the patients had 350G variants. Our results, however, are
in good agreement with those of a study by Sathish et al. (39) from
the southeastern part of India.
We have observed that nucleotide positions 83 to 144, 146 to
285, and 351 to 526 are the most conserved regions of HPV-16
E6, which seems to be important for silencing E6 expression
using short interfering RNA and/or ribozyme treatment. Also,
the amino acids located in these regions may play an important
immunogenic role in new vaccine strategies (21). The amino
acid substitutions analyzed in this study are Q14H, H78Y, and
L83V, and they also were observed by Sto¨ppler and his group
(47). Most interestingly, 100% distribution (42/42) of the
HPV-16 E6 E variant 350G was detected; it was found either
alone (81%; 34/42) or in combination with additional E6
gene mutations. The E6 variations G145T and C335T that
were detected with 350G also have been observed in AA,
NA, Af1, and Af2 lineages. A novel E6 gene mutation,
T527A (S142T), that replaced serine with threonine was
observed in only one (2.4%) case. In sharp contrast to a
report from China that showed a high prevalence of the
HPV-16 As lineage (55), our results as well as the reports of
other authors from India (36, 39) suggest the complete
absence of the As lineage in India.
HPV-16 E7 gene mutation has been reported to be rare in
various geographic and ethnic populations around the world
(16, 36). However, several studies, particularly from Japan,
Korea, and Indonesia, have reported a high frequency of E7
gene mutation (65 to 75%) in cervical cancer patients (9, 45).
Interestingly, a recent report from China showed that 100% of
cervical cancer cases had nucleotide variations in the HPV-16
E7 region (55). In contrast, we observed a highly conserved E7
region; as high as 86.7% of patients showed no sequence vari-
ation, and only 13.3% showed variation in the form of silent
mutations, thus having no effect on proteins. Because of the
conserved E7, it can be far more easily targeted in order to
silence its effects at the RNA or protein level. The most fre-
quently reported E7 variation, A647G, also has been found to
be completely absent in India. Any change in the two trans-
forming genes E6 and E7 may lead to altered biological func-
tion and oncogenicity of the proteins encoded, which can affect
the natural history of HPV infection (13).
Examinations of the L1 gene also did not reveal any signif-
icant variations, and 64.5% (20/31) of the samples showed the
prototype sequence. Very few reports are available on the
HPV-16 L1 variants (9, 53, 54, 56), and none are from south
Asia. Interestingly, the common L1 variant T6862C observed
in all previous studies was not detected; instead, four novel
nucleotide variations, two silent and two missense mutations,
at codons 343, 351, 423, and 429 were detected (Table 2). This
is indicative of the hypervariability of the L1 gene in this
region. The importance of the most frequently observed L1
gene variation, A6695 (T353P), lies in the fact that a polar
uncharged amino acid (threonine) is replaced by a nonpolar
aliphatic amino acid that may have an effect on the structure or
function of the L1 protein, which may play an important role in
immune recognition and vaccine development strategies.
Amino acid changes among molecular variants also have been
shown to affect the efficiency of HPV-16 L1 proteins to self
assemble into virus-like particles (25, 49). This variability could
lead to conformational changes within epitopes relevant for
viral neutralization (44).
The LCR, which contains the upstream regulatory region, is
the binding site of various cellular and viral transcription fac-
tors that either activate or suppress the p97 promoter activity,
which regulates the transcription of various HPV-16 genes,
especially the E6 and E7 oncogenes. It has been reported to be
the most variable segment of the HPV-16 genome in different
populations (23, 26, 53, 56). We observed a similar pattern, as
75% (45/60) of patients had 17 different LCR variants, of
which four (C13T, A7636C, C7678T, and G7799A) were found
to be novel types, including an A7636C substitution that was
detected in the AP1 binding site (4.4%). Since LCR is the
major site for the transcriptional control of the virus, studies
are under way to correlate the observed alterations with the
biological/biochemical properties and different clinicopatho-
logical features of the disease. The number of nucleotide al-
terations was highest for the LCR, followed by the L1, E6, and
E7 genes, and this is in good agreement with results from a
previous report (56). The most frequently observed mutation
in the LCR was G7521A, which is located at the YY1 binding
site, was found in as many as 91% of cases, and causes the
repression of HPV transcription. This mutation has been
found to be uniformly distributed in the majority of cervical
cancer patients throughout the world (26, 41, 53, 56) but is not
found in asymptomatic carriers (41). Mutations in the YY1
binding sites have been shown to promote the p97 promoter
activity by three- to sixfold (12, 29). It also has been shown to
quench AP1 activity, thereby repressing HPV-16 transcription
(35). The role of mutation at the YY1 binding site in cancer
cases assumes a greater importance, as this mutation is absent
from noncancerous lesions and asymptomatic carriers (42).
The presence of mutations in the binding sites of various tran-
scription factors or in their close vicinities is intriguing, since
these factors enhance the transcription activity of HPV-16
oncogenes. A low frequency (4.4%) of mutation found in the
Oct-1 binding site appears to be important, since Oct-1 is an
important part of the basal transcriptional machinery and is
known to down-regulate HPV expression (43).
Most interestingly, when the distribution of HPV-16 variants
with respect to E6, E7, and L1 genes and the LCR was com-
pared to that of different lineages, an extremely high preva-
lence of the E lineage (85, 86.7, 67.7, and 63.3%, respectively)
and the complete absence of the As lineage (36, 39) were
observed. The occurrence of AA and NA classes in this study
is in accordance with other studies from the southern part of
India (56). It is important that HPV variants are correlated
with the severity of lesions through follow-up data to elucidate
the biological significance of HPV-16 variants during cervical
carcinogenesis, thus delineating the utility of such correlations
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in developing reliable diagnostics and effective therapeutics,
including vaccines against HPV.
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